Implantable 'charging station' boosts fight against cancer

Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease. But many ...
Las Vegas Sun

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potentialNEW YORK, ...

Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynK…

Verismo Therapeutics, a clinical-stage immuno-oncology company developing a novel multi-chain KIR-CAR platform technology, ...

Universal, ready-to-use immunotherapy detects and destroys endometrial cancer in preclinical tests

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades. The most ...
CURE

CAR-NKT Immunotherapy Eliminates Endometrial Tumors in Preclinical Models

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and ...
Pharmabiz

MiNK Therapeutics collaborates with C-Further to advance PRAME-targeted iNKT cell therapy for paediatric cancer

MiNK Therapeutics collaborates with C-Further to advance PRAME-targeted iNKT cell therapy for paediatric cancer: New York Thursday, March 12, 2026, 10:00 Hrs [IST] MiNK Therapeuti ...